UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid Tumors

NCT06760117 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Pediatric Solid Tumor

Interventions

DRUG: Irinotecan (CPT-11)
DRUG: Temozolomide (TMZ)
DRUG: Vincristine

Sponsor

Sun Yat-sen University